Bunge Global (BG) Proxy filing summary

Executive summary

• The 2026 proxy filing details a year of transformation, highlighted by the completion of the Viterra combination, which expanded the global platform and improved the risk profile, with early integration synergies and credit rating upgrades reinforcing the transaction's rationale.

• The Board prioritized strategy, risk oversight, governance, and long-term value creation, overseeing disciplined capital allocation, divestitures, and capital returns, including $459M in dividends and $551M in share repurchases in 2025.

• Sustainability remained integral, with progress on non-deforestation, supply chain traceability, and readiness for new regulatory requirements, while human capital and safety were emphasized through talent development and succession planning.

Voting matters and shareholder proposals

• Shareholders are asked to approve financial statements, earnings appropriation, a $2.88/share dividend in four installments, discharge of Board and management from liability, election of directors, reelection of the Chair, and reelection of HRCC members.

• Advisory votes include say-on-pay, Swiss compensation report, and Swiss non-financial matter report; appointment of auditors and election of the independent voting representative are also on the agenda.

• All proposals are recommended for approval by the Board.

Board of directors and corporate governance

• The Board consists of 12 directors, with 42% female representation and an average tenure of 3.6 years; 11 of 12 are independent.

• Five new directors joined post-Viterra, bringing expertise in agribusiness, supply chains, technology, and risk management.

• Board refreshment, diversity, and skills alignment are ongoing priorities; robust onboarding and annual self-assessments are conducted.

• Shareholder rights include annual director elections, proxy access, and the ability for 5% holders to call special meetings; there is no poison pill.